title: [Hypolipidemic action of F-1394, an acyl-CoA: cholesterol acyltransferase (ACAT) inhibitor, in high-fat diet fed beagle dogs].
abstract: In the present study, we investigated the hypolipidemic effect of F-1394, a potent and selective inhibitor of acyl-CoA: cholesterol acyltransferase (ACAT), in dogs fed with a high-fat diet consisting of regular foods, 5% cholesterol and 16% fat. The serum cholesterol levels in dogs reached the steady-state 1 week after the start of feeding of a high-fat diet and were about 2-fold greater than those in normolipidemic dogs. Graded administration of the doses of F-1394 (1-30 mg/kg/d) to the dogs fed with a high-fat diet prevented the elevation of serum cholesterol levels. In the hyperlipidemic dogs fed with a high-fat diet for 14 d before the start of the administration of F-1394, the oral administration of F-1394 at a dose of 1, 3 or 10 mg/kg/d for 21 d reduced the serum cholesterol levels in a dose-dependent manner. The estimated ID50 value was 7.2 +/- 0.3 mg/kg/d p. o. (12.1 +/- 0.5 mol/kg/d p. o.). F-1394 did not affect the body weight and no diarrhea was observed by the administration of F-1394. F-1394 at a dose of 10 mg/kg/d or more also significantly inhibited the increase of serum triglyceride levels 3 h after the feeding of high-fat diet. These results suggest that F-1394 inhibits the ACAT activity in the canine small intestine and, subsequently, the inhibition of ACAT activity contributes much to the prevention of cholesterol absorption via the gut, resulting in a decrease in serum cholesterol levels in the dogs fed with high-fat diet. Furthermore, F-1394 may also have an inhibitory effect on the triglyceride absorption via the gut, and the therapeutical use for postprandial hypertriglyceridemia is expected.
authors.affiliation: Pharmaceuticals Research Laboratories, Fujirebio Inc., Tokyo, Japan.
authors.forename: J
authors.initials: J
authors.lastname: Kusunoki
authors.forename: K
authors.initials: K
authors.lastname: Aragane
authors.forename: T
authors.initials: T
authors.lastname: Kitamine
authors.forename: T
authors.initials: T
authors.lastname: Yamaura
authors.forename: H
authors.initials: H
authors.lastname: Ohnishi
mesh_terms: D000818:Animals; D002784:Cholesterol / Q000097:blood; D003510:Cyclohexanes / Q000494:pharmacology* / Q000627:therapeutic use*; D003864:Depression, Chemical; D004041:Dietary Fats / Q000008:administration & dosage; D004146:Dioxanes / Q000494:pharmacology* / Q000627:therapeutic use*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy*; D008297:Male; D002785:Sterol O-Acyltransferase / Q000037:antagonists & inhibitors*; D014280:Triglycerides / Q000097:blood
chemical_list: D003510:Cyclohexanes; D004041:Dietary Fats; D004146:Dioxanes; C094918:F 1394; D014280:Triglycerides; D002784:Cholesterol; D002785:Sterol O-Acyltransferase